Navigation Links
BioNeutral's Ygiene(TM) New Hospital Grade Disinfectant Will Save Lives and Billions of Dollars Annually at Health Care Facilities Around the World
Date:8/19/2008

Ygiene(TM) Hospital Grade antimicrobial sets the new global standard to

eradicate (100% kill) in seconds the most difficult and lethal microorganisms commonly found in health care facilities, including MRSA and

C. difficile

NEWARK, N.J., Aug. 19 /PRNewswire/ -- BioNeutral announces successful testing of its Ygiene(TM) Hospital Grade antimicrobial against antibiotic-resistant microorganisms and spore forms of microorganisms which represent the major source of hospital acquired infections. In the US, Methicillan Resistant Staphylococcus Aureus (MRSA), Vancomycin-resistant Enterococci, Pan-resistant Klebsiellia pneumoniae and Clostridium difficile are but a few of the various lethal microorganisms present in hospital environments which contribute to over two-and-a-half million hospital acquired infections and one-hundred-thousand deaths annually. Using Ygiene(TM) Hospital Grade antimicrobial to routinely disinfect all areas in health care facilities can save many lives and billions of dollars annually in this global problem. Ygiene(TM) Hospital Grade antimicrobial has been found to completely eradicate these harmful microorganisms in seconds, and is still safe for the environment.

Dr. Philip Tierno, Principal Investigator and Head of Microbiology and Immunology at the Langone NYU Medical Center, has stated regarding Ygiene(TM) Hospital Grade antimicrobial: "No chemical formulation I have ever tested gives a quicker and more complete kill, has a broader spectrum of activity and is more 'green.'"

Dr. Andy Kielbania, Chief Scientist at BioNeutral, stated, "Despite the use of Lysol(R), Clorox(R) bleach, Oxivir(TM)Tb, Medica DC Germicidal Solution, Asepticare(R) TB+II, Germ Control 24 by Pure Biosciences and many other commercial disinfectants, the epidemic of infections continues in health care facilities. Most of these products are not sporicidal and either have no effect on the more difficult organisms,
'/>"/>

SOURCE BioNeutral Laboratories Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. U.S. Hospital Sales Opportunities Maximized Through Functional Optimization
2. Bioness Announces NESS H200 and L300 Systems to Be Available at 88 HealthSouth Hospitals Nationwide
3. St. Lukes Episcopal Hospital to Add CyberKnife System to Treatment Offerings
4. FDA Advisory Committee Provides Opinion of DORIBAX(TM) for the Treatment of Hospital-Acquired Pneumonia
5. AMT Starts Collaboration With St. Jude Childrens Research Hospital on Gene Therapy for Hemophilia B. Company Accesses Exclusive Commercial Rights to Final Therapy
6. U.S. News Media Group Releases 19th Edition of Americas Best Hospitals
7. Isabel Healthcare Adds Hospitals in Wisconsin & Minnesota
8. Low-Power Ultra Wideband (UWB) Technology Best RFID Choice for Hospitals to Minimize Interference Threat
9. Website and Blog Increase Placement for Medical Sales Recruiter - Providing Sales Winners Calling on the Hospital, Lab and Physician Call Point
10. Website and Blog Increase Placement for Medical Sales Recruiter - Providing Sales Winners Calling on the Hospital, Lab and Physician Call Point
11. Number of Patients Treated with an Antibiotic for MRSA Within U.S. Acute Care Hospitals Increased 8 Percent from 2006 to 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... Axovant Sciences Ltd. (NYSE:  AXON), a leading clinical-stage biopharmaceutical company ... at three investor conferences: , Wednesday, September 9 ... New York at the New York ... at the BioCentury NewsMakers Conference in New York ... , Thursday, September 17 at 9:30 AM at the ...
(Date:9/2/2015)... ... September 02, 2015 , ... ... managed with the use of special anti-vascular endothelial growth factor agents given by ... patients, currently does not have a scientific protocol for the many millions diagnosed ...
(Date:9/2/2015)... Mass. (PRWEB) , ... September 02, 2015 , ... ... includes development of botanical and plant-derived compounds. BCC Research reveals in its ... past 2020 because this market defines the category and generates the most market ...
(Date:9/2/2015)... , September 2, 2015 ... ("BioLight" or the "Company"), a firm that invests ... and cancer diagnostics, announced today that presentations highlighting ... will be delivered at the Ophthalmology Futures European ... Society of Cataract & Refractive Surgeons ("ESCRS"), both ...
Breaking Biology Technology:Axovant Sciences To Present At Upcoming Investor Conferences 2Axovant Sciences To Present At Upcoming Investor Conferences 3StemCell GeneticMed Announces That It Has Started Stem Cell Treatments for Age Related Dry Macular Degeneration (AMG) 2Plant-derived Compounds Poised to Assume Greater Role in Global Drug Markets, According to BCC Research 2Plant-derived Compounds Poised to Assume Greater Role in Global Drug Markets, According to BCC Research 3Presentations to Highlight BioLight's IOPtiMate[TM] System at Upcoming European Ophthalmology Conferences 2Presentations to Highlight BioLight's IOPtiMate[TM] System at Upcoming European Ophthalmology Conferences 3
... Inc. (Sparta),the maker of TrackWise(R), and the market ... that its TrackWise solution has,been chosen by Protherics ... manufacturing and marketing of specialized products for,critical care ... handling,processes. TrackWise provides organizations with a single, ...
... Oct. 24 Human Genome,Sciences, Inc. (Nasdaq: HGSI ... to discuss its financial results for the quarter ended,September ... on Thursday,November 1, 2007. (Logo: http://www.newscom.com/cgi-bin/prnh/20010612/HGSLOGO ) ... management and will be,held on Thursday, November 1, 2007, ...
... Call on Thursday, October 25, 2007 at ... ... Keryx Biopharmaceuticals,Inc. (Nasdaq: KERX ), a biopharmaceutical company focused ... the treatment of life-threatening,diseases, including diabetes and cancer, today announced its ...
Cached Biology Technology:Protherics UK Ltd. Chooses TrackWise for Corrective Action and Preventive Action (CAPA) Management 2Human Genome Sciences To Sponsor Conference Call To Discuss Third Quarter 2007 Financial Results 2Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2007 Financial Results 2Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2007 Financial Results 3Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2007 Financial Results 4Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2007 Financial Results 5Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2007 Financial Results 6
(Date:8/20/2015)... SANTA CLARA, Calif. , Aug. 20, 2015 ... based company focused on improving the user experience ... voice and vision technologies, today announced that its ... and voice biometric authentication software to be ... Alliance tested TrulySecure for compliance with the FIDO ...
(Date:8/19/2015)... , Aug. 19, 2015  VOXX International Corporation ... has entered into a Definitive Agreement to purchase ... iris authentication market leader EyeLock through an acquiring ... have a controlling interest in the acquiring entity. ... completion of due diligence.  Expanding on its existing ...
(Date:8/18/2015)... 17, 2015 Research and Markets ( ... "Global Biometric Authentication & Identification Market: Focus ... Forecast, 2015-2020" report to their offering. ... systems market is expected to grow at an ... and generate over $25 billion (approximately) by 2020 ...
Breaking Biology News(10 mins):TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 2TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 3TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 4TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 5VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 2VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 3VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 4VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 5Global Biometric Authentication & Identification Market 2015: Focus On Modality, Motility & Application - Estimation & Forecasts to 2020 for the $25 Billion Industry 2
... 16, 2011 A new episode in the American ... podcast series spins a real-life tale in which spider ... the use of gene therapy in everyday medicine. ... explains in non-technical language that gene therapy involves the ...
... KAN. -- A Kansas State University research group is ... young children and prevent childhood obesity. The researchers ... head -- have developed a program called HOP,N Home, ... Nutrition at Home. The researchers have been working on ...
... headed by Prof. Johanna Ivaska (University of Turku and VTT ... of Turku and the National Institute for Health and Welfare) ... Published in a leading journal, the study concludes ... and of lung and prostate cancer cells. It is likely ...
Cached Biology News:New American Chemical Society podcast: Genetically-engineered spider silk for gene therapy 2Research aims to prevent obesity by reaching parents, young children through child care 2Research aims to prevent obesity by reaching parents, young children through child care 3
Rabbit polyclonal to MAP3K12 ( Abpromise for all tested applications). Antigen: Synthetic peptide conjugated to KLH from the C-terminal region of human MAP3K12 Entrez Gene ID: 7786 Swiss ...
Phosphatidylinositol transfer protein beta isoform (PtdIns transfer protein beta) (PtdInsTP) (PI-TP-beta). [Source:Uniprot/SWISSPROT;Acc:P48739] Antigen: Recombinant Protein Epitope Signature Tag...
Desmosomal Protein Immunogen: Full length, native protein purified from human epidermal keratins. Storage: -20 C, Avoid Freeze/Thaw Cycles...
Mouse monoclonal [SPM217] to Secretory Component Glycoprotein ( Abpromise for all tested applications)....
Biology Products: